Enliven Therapeutics (NASDAQ:ELVN) Shares Up 10.8% - Still a Buy?

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s stock price rose 10.8% during mid-day trading on Tuesday . The stock traded as high as $17.77 and last traded at $17.97. Approximately 289,688 shares changed hands during mid-day trading, an increase of 9% from the average daily volume of 264,779 shares. The stock had previously closed at $16.22.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lifted their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research note on Friday, March 21st.

Enliven Therapeutics Price Performance

The firm has a market cap of $892.36 million, a price-to-earnings ratio of -9.58 and a beta of 1.03. The firm's 50 day moving average price is $19.37 and its 200-day moving average price is $22.67.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The firm had revenue of $0.03 million for the quarter. Analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $16.07, for a total transaction of $80,350.00. Following the sale, the insider now directly owns 997,688 shares of the company's stock, valued at approximately $16,032,846.16. The trade was a 0.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Anish Patel sold 6,667 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $21.93, for a total value of $146,207.31. Following the completion of the transaction, the chief operating officer now directly owns 329,977 shares of the company's stock, valued at approximately $7,236,395.61. The trade was a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,751 shares of company stock valued at $1,340,713 over the last quarter. 29.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Large investors have recently made changes to their positions in the company. Polar Capital Holdings Plc raised its stake in shares of Enliven Therapeutics by 267.6% in the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after acquiring an additional 1,739,668 shares during the last quarter. Boxer Capital Management LLC acquired a new stake in Enliven Therapeutics during the 4th quarter valued at $15,106,000. Lord Abbett & CO. LLC bought a new position in Enliven Therapeutics in the 3rd quarter valued at $8,199,000. Janus Henderson Group PLC grew its holdings in shares of Enliven Therapeutics by 27.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock worth $30,001,000 after purchasing an additional 290,153 shares during the last quarter. Finally, FMR LLC increased its stake in shares of Enliven Therapeutics by 3.2% in the fourth quarter. FMR LLC now owns 6,495,871 shares of the company's stock valued at $146,157,000 after buying an additional 199,692 shares in the last quarter. Institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.